Newsletter | October 23, 2026

10.23.26 -- China's Biotech Impact, Clinical Research Trends, AI & More

VIDEO

China's Impact On U.S. And European Biotech Fundraising

From Life Science Leader Live event “Crossing The Valley Of Death: New Funding Options For Preclinical And Early-Stage Drug Development,” learn how high-quality Chinese assets are reshaping biotech funding and partnerships.

INDUSTRY INSIGHTS

We Made Five Predictions For Clinical Research Last Year. Here's What Happened

Review 2025’s gap between AI discovery and trial execution, highlighting legislative and FDA shifts to help sponsors operationalize participant experience for 2026.

AI, Biotech, And Investment A Opportunity For Research Universities

AI is accelerating drug discovery, but data limitations threaten progress. Strong leadership and coordinated support across research, government, investment, and industry will be essential.

Building The Blueprint: What Psychedelic Trials Need Now

Discover how leading experts are addressing recent regulatory reviews to shape the next phase of psychedelic clinical research.

Site Selection Solutions Using Patient Insights For Rare Disease Trials

Uncover recruitment opportunities and strengthen patient engagement with a data-driven approach to rare disease site selection, enrollment, and retention.

Accelerating ADC Analytical Method Development Through Platform Innovation

Leverage a platform-based analytical development strategy to accelerate ADC IND readiness through early CQA identification, reduced development risk, and streamlined progression from development to patients.

Curia's Approach To Regulatory Compliance In Korea

Navigating Asian pharma markets requires alignment with local regulations. Standardized documentation, facility registrations, and strong quality systems support compliance and reliable supply.

Connect With Life Science Leader: